Publicacións nas que colabora con Montserrat Andreu García (34)

2019

  1. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

2018

  1. Detection of serrated lesions in proximal colon by simulated sigmoidoscopy vs faecal immunochemical testing in a multicentre, pragmatic, randomised controlled trial

    United European Gastroenterology Journal, Vol. 6, Núm. 10, pp. 1527-1537

2017

  1. Candidate predisposing germline copy number variants in early onset colorectal cancer patients

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 625-632

  2. Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs

    United European Gastroenterology Journal, Vol. 5, Núm. 2, pp. 255-260

2016

  1. Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC)

    Carcinogenesis, Vol. 37, Núm. 8, pp. 751-758

  2. Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening

    Digestive and Liver Disease, Vol. 48, Núm. 5, pp. 542-551

  3. Incidence of advanced neoplasia during surveillance in high- and intermediate-risk groups of the European colorectal cancer screening guidelines

    Endoscopy, Vol. 48, Núm. 11, pp. 995-1002

2015

  1. Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer

    Journal of Medical Genetics, Vol. 52, Núm. 7, pp. 498-502

2014

  1. A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer

    Human Genetics, Vol. 133, Núm. 5, pp. 525-534

  2. Effect of oral anticoagulants on the outcome of faecal immunochemical test

    British Journal of Cancer, Vol. 110, Núm. 5, pp. 1334-1337

  3. Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening

    Cancer Causes and Control, Vol. 25, Núm. 8, pp. 985-997

  4. Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests

    Clinical Gastroenterology and Hepatology, Vol. 12, Núm. 10, pp. 1708-1716.e4

2013

  1. A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12

    BMC Genomics, Vol. 14, Núm. 1

  2. BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern european populations

    Carcinogenesis, Vol. 34, Núm. 2, pp. 314-318

  3. BMPR1A mutations in early-onset colorectal cancer with mismatch repair proficiency

    Clinical Genetics

  4. Corrigendum

    Carcinogenesis

  5. Effect of aspirin and antiplatelet drugs on the outcome of the fecal immunochemical test

    Mayo Clinic Proceedings

  6. Genetic susceptibility variants associated with colorectal cancer prognosis

    Carcinogenesis, Vol. 34, Núm. 10, pp. 2286-2291

  7. Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals

    Gastrointestinal Endoscopy, Vol. 78, Núm. 2

  8. Risk of advanced proximal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-based strategies.

    Journal of the National Cancer Institute, Vol. 105, Núm. 12, pp. 878-886